Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Champions Oncology

Request full access

Personalize Each Patient窶冱 Cancer Treatment Therapy

Herzliya, IsraelFounded 2007Biotech & Life Sciences

About Champions Oncology

In 2007, Johns Hopkins oncologist Dr. David Sidransky founded Champions Oncology with a core mission: to personalize cancer treatment. The company centered its work on an innovative concept known as mouse avatars, or TumorGrafts. This process involves implanting a living sample of a patient's tumor into an immunodeficient mouse. Once the tumor grows, it's propagated into more mice, which are then used to test various cancer drugs and combinations to see what is most effective against that specific tumor. The company's journey began to take a significant turn when it acquired Biomerk, Inc. in May 2007, sharpening its focus on this new line of business. Initially named Champions Biotechnology, it rebranded to Champions Oncology in 2011 to better reflect its strategic direction. The company went public, trading on the NASDAQ under the symbol CSBR. A notable public offering in June 2016 raised approximately $4.39 million, which was earmarked for the development of its TumorGraft platform and for working capital. Champions Oncology operates primarily as a contract research organization (CRO), providing preclinical research services to pharmaceutical and biotech firms. This model allows drug developers to outsource complex tumor studies, leveraging Champions' specialized platform. Today, the company continues to innovate, expanding its services and presenting its research at major scientific conferences, solidifying its role in the advancement of personalized oncology.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2003
Outcome tier
Colt$25–100M revenue

Champions Oncology in the Herzliya ecosystem

Live from Dealroom

The Champions Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

Team profiled 22 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
8 countries with
team presence
🇺🇸 United States81.9%
🇮🇹 Italy5.4%
🇨🇦 Canada4%
🇬🇧 United Kingdom2.7%
🇮🇱 Israel2%
Top 5 of 8 shown
Web traffic by country
11K monthly visits
across markets
🇺🇸 United States52.7%
🏳️ Korea11.8%
🏳️ Republic of11.8%
🇬🇧 United Kingdom9.1%
🇮🇳 India6.4%
Top 5 markets shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Champions Oncology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Champions Oncology on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.